The use of stem cells for the treatment of autoimmune diseases

Rosa, Sílvia Barcellos; Voltarelli, Júlio César; Pranke, Patrícia

doi:10.1590/s0100-879x2006005000166

Cited by 35 publications

(25 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Animal experiments indicated the T lymphocytes in transplants are correlated with the recurrence of the disease [11][12][13][14][15]. To date, most international scholars use the cell grading system as a way of eliminating T lymphocytes in hematopoietic stem cell transplantation.…”

Section: Discussionmentioning

confidence: 99%

Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus

Sun

Zeng

et al. 2008

Front. Med. China

View full text Add to dashboard Cite

The aim of this study is to explore the effectiveness of autologous peripheral hematopoietic stem-cell transplantation in the treatment of refractory pemphigus. A 35-year-old male patient presented with a 4-year history of recurrent bullae on his trunk and extremities. The diagnosis of pemphigus was made on the basis of the clinical, histologic and immunofluorescence findings. The patient had shown resistance to conventional therapy with glucocorticoid and immunosuppressive agents. Two months before admission, he complained of hip joint pain. X-ray and CT scan revealed aseptic necrosis of the femoral head. Stem-cell mobilization was achieved by treatment with cyclophosphamide, granulocyte colony-stimulating factor (G-CSF) and rituximab. Peripheral blood stem cells were collected via leukapheresis and cryopreserved for later use. Immunoablation was accomplished by using cyclophosphamide (200 mg/kg; divided into 50 mg/kg on days -5, -4, -3, and -2), antithymocyte globulin (ATG; 10 mg/kg; divided into 2.5 mg/kg on days -6, -5, -4, and -3), and rituximab (1200 mg/d; divided into 600 mg/d on days 0 and 7). Autologous peripheral hematopoietic stem cell transplantation was followed by reconstitution of the immune system which was monitored by flow cytometry. The glucocorticoid was withdrawn immediately after transplantation. The pemphigus titer turned negative 6 weeks after transplantation and remained negative. The patient was in complete drug-free remission with no evidence of residual clinical or serological activity of pemphigus during 1 year of followup. The patient's response suggests that autologous peripheral hematopoietic stem cell transplantation may be a potential ''cure'' for refractory pemphigus. However, further studies are needed to evaluate the risk-benefit ratio of this approach in patients with pemphigus showing resistance to conventional therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus

Sun

Zeng

et al. 2008

Front. Med. China

View full text Add to dashboard Cite

show abstract

“…Therefore, HSCT for RA patients should be considered with extra caution [95]. Over the past decade, novel biologic agents for RA have significantly reduced symptoms and disability and enhanced QOL.…”

Section: Ramentioning

confidence: 99%

Stem Cell Therapy in Autoimmune Rheumatic Diseases: a Comprehensive Review

Liu

Shu

Kenny

et al. 2014

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The clinical management of autoimmune rheumatic diseases (ARD) has undergone significant changes in the last few decades, leading to remarkable improvements in clinical outcomes of many patients with mild to moderate ARD. On the other hand, severe refractory ARD patients often have high morbidity and mortality. Extensive basic research and clinical evidence has opened the door to new encouraging perspectives, such as the establishment of a role of stem cell transplantation (SCT) in the strategic management of ARD. Given the great heterogeneity of ARD, it is difficult to assign an optimal SCT regimen to all ARD patients. SCT remains a challenging mode of therapy in ARD patients from the standpoints of both efficacy and safety. As the clinical data of SCT in ARD increases and as we improve our understanding of stem cell biology and the downstream effects on the immune system, the future is promising for the development of optimal personalized SCT regimens in ARD.

show abstract

“…ТСК стала значимой сначала в онкогематоло-гии, затем началось изучение ее эффективности у боль-ных с аутоиммунными заболеваниями, резистентными к стандартному лечению [6]. К 2004 г. в базах данных Ев-ропы и Северной Америки накоплена информация при-мерно о 800 процедурах трансплантации гемопоэтиче-ских стволовых клеток (ГСК), выполненных у больных с различными аутоиммунными заболеваниями [7]: рассе-янным склерозом [8], ревматоидным артритом [9], юве-нильным идиопатическим артритом [10], системной красной волчанкой [11] и др.…”

unclassified

Stem Cell Transplantation as a Possible Strategy for Treating Standard Therapy-Resistant Ankylosing Spondylitis

Гайдукова¹,

Ushakova²,

Ребров³

2016

RJTAO

View full text Add to dashboard Cite

Анкилозирующий спондилит (АС) -хроническое вос-палительное заболевание из группы спондилоартритов (СпА), характеризующееся обязательным поражением кре-стцово-подвздошного сочленения (КПС) и/или позвоноч-ника с потенциальным исходом в анкилоз, с частым вовле-чением в патологический процесс энтезисов и перифериче-ских суставов [1].Целью лечения пациента со СпА, включая АС, явля-ется достижение ремиссии или, в качестве альтернатив-ной цели, низкой активности заболевания с улучшением качества жизни и замедлением прогрессирования [2]. До-стижение клинико-лабораторной ремиссии и ремиссии по данным магнитно-резонансной томографии (МРТ) возможно на фоне длительной и зачастую дорогостоящей

show abstract

The use of stem cells for the treatment of autoimmune diseases

Abstract: Autoimmune diseases constitute a heterogeneous group of conditions commonly treated with anti-inflammatory, immunosuppressant and immunomodulating drugs, with satisfactory results in most cases.

Cited by 35 publications

References 54 publications

Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus

Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus

Stem Cell Therapy in Autoimmune Rheumatic Diseases: a Comprehensive Review

Stem Cell Transplantation as a Possible Strategy for Treating Standard Therapy-Resistant Ankylosing Spondylitis

Contact Info

Product

Resources

About